blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4334308

EP4334308 - LACTONE AND LACTAM CONTAINING COMPOUNDS USEFUL AS IMMUNOMODULATORS [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  09.02.2024
Database last updated on 14.09.2024
FormerThe international publication has been made
Status updated on  11.11.2022
Formerunknown
Status updated on  17.06.2022
Most recent event   Tooltip12.07.2024Change: Validation statespublished on 14.08.2024  [2024/33]
12.07.2024Change - extension statespublished on 14.08.2024  [2024/33]
Applicant(s)For all designated states
Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton, NJ 08543 / US
[2024/11]
Inventor(s)01 / WANG, Tao
Farmington, Connecticut 06032 / US
02 / ZHANG, Zhongxing
Cambridge, Massachusetts 02142 / US
03 / YIN, Zhiwei
Glastonbury, Connecticut 06033 / US
 [2024/11]
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[2024/11]
Application number, filing date22728999.804.05.2022
[2024/11]
WO2022US27615
Priority number, dateUS202163184240P05.05.2021         Original published format: US 202163184240 P
[2024/11]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2022235754
Date:10.11.2022
Language:EN
[2022/45]
Type: A1 Application with search report 
No.:EP4334308
Date:13.03.2024
Language:EN
The application published by WIPO in one of the EPO official languages on 10.11.2022 takes the place of the publication of the European patent application.
[2024/11]
Search report(s)International search report - published on:EP10.11.2022
ClassificationIPC:C07D403/12, C07D403/14, C07D407/12, C07D407/14, A61K31/44, A61K31/445, A61P35/00, C07D413/14
[2024/11]
CPC:
C07D403/12 (EP); C07D405/14 (KR); A61K31/4545 (KR);
A61P35/00 (KR); A61P37/02 (KR); C07D401/12 (KR);
C07D401/14 (KR); C07D403/14 (EP); C07D405/12 (KR);
C07D407/12 (EP); C07D407/14 (EP); C07D413/14 (EP,KR) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2024/11]
TitleGerman:LACTON UND LACTAM ENTHALTENDE VERBINDUNGEN ALS IMMUNOMODULATOREN[2024/11]
English:LACTONE AND LACTAM CONTAINING COMPOUNDS USEFUL AS IMMUNOMODULATORS[2024/11]
French:COMPOSÉS CONTENANT DE LA LACTONE ET DU LACTAME UTILES EN TANT QU'IMMUNOMODULATEURS[2024/11]
Entry into regional phase30.11.2023National basic fee paid 
30.11.2023Designation fee(s) paid 
30.11.2023Examination fee paid 
Examination procedure30.11.2023Examination requested  [2024/11]
30.11.2023Date on which the examining division has become responsible
18.01.2024Amendment by applicant (claims and/or description)
Fees paidRenewal fee
13.03.2024Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[A]WO2015034820  (BRISTOL MYERS SQUIBB CO [US]) [A] 1-12* example -; claim - *;
 [A]WO2020047035  (CHEMOCENTRYX INC [US]) [A] 1-12 * example -; claim - *;
 [A]EP3658522  (CHEMOCENTRYX INC [US]) [A] 1-12 * example -; claim - *
by applicantUS5811097
 US5837243
 US5922845
    - KEIR MEBUTTE MJFREEMAN GJ et al., Annu. Rev. Immunol., (20080000), page 26
    - BUTTE MJ et al., Immunity, (20070000), vol. 27, pages 111 - 122
    - PATERSON AM et al., J Immunol., (20110000), vol. 187, pages 1097 - 1105
    - YANG J. et al., J Immunol., (20110801), vol. 187, no. 3, pages 1113 - 9
    - DONG HCHEN L, JMolMed, (20030000), vol. 81, no. 5, pages 281 - 287
    - DONG HSTROME SESALAMOA DR et al., Nat Med., (20020000), vol. 8, no. 8, pages 793 - 800
    - BARBER DLWHERRY EJMASOPUST D et al., Nature, (20060000), vol. 439, no. 7077, pages 682 - 687
    - S. J. HAS. N. MUELLERE. J. WHERRY et al., The Journal of Experimental Medicine, (20080000), vol. 205, no. 3, pages 543 - 555
    - A. C. FINNEFROCKA. TANGF. LI et al., The Journal of Immunology, (20090000), vol. 182, no. 2, pages 980 - 987
    - M. -Y. SONGS. -H. PARKH. J. NAMD. -H. CHOIY.-C. SUNG, The Journal of Immunotherapy, (20110000), vol. 34, no. 3, pages 297 - 306
    - HAHNE, M., Science, (19960000), vol. 274, pages 1363 - 1365
    - A Textbook of Drug Design and Development, Harwood Academic Publishers, (19910000), pages 113 - 191
    - IWAI, Int. Immunol., (20050000), vol. 17, pages 133 - 144
    - HE et al., J. Immunol., (20040000), vol. 173, pages 4919 - 28
    - ROSENBERG, S., "Development of Cancer Vaccines", ASCO Educational Book Spring, (20000000), pages 60 - 62
    - LOGOTHETIS, C., ASCO Educational Book Spring, (20000000), pages 730 - 738
    - TAMURA, Y. et al., Science, (19970000), vol. 278, pages 3023 - 3043
    - DRANOFF et al., Proc. Natl. Acad. Sci. U.S.A., (19930000), vol. 90, pages 3539 - 43
    - ROSENBERG, S A, Immunity, (19990000), vol. 10, pages 281 - 7
    - KIM, N et al., Science, (19940000), vol. 266, pages 2011 - 2013
    - SUOT, RSRIVASTAVA, P, Science, (19950000), vol. 269, pages 1585 - 1588
    - NESTLE, F. et al., Nature Medicine, (19980000), vol. 4, pages 328 - 332
    - KUGLER, A. et al., Nature Medicine, (20000000), vol. 6, pages 332 - 336
    - MOKYR, M. et al., Cancer Research, (19980000), vol. 58, pages 5301 - 5304
    - KEHRL, J. et al., J. Exp. Med., (19860000), vol. 163, pages 1037 - 1050
    - HOWARD, M.O'GARRA, A., Immunology Today, (19920000), vol. 13, pages 198 - 200
    - RIDGE, J. et al., Nature, (19980000), vol. 393, pages 474 - 478
    - ITO, N. et al., Immunobiology, (20000000), vol. 201, no. 5, pages 527 - 40
    - WEINBERG, A., Immunol, (20000000), vol. 164, pages 2160 - 2169
    - MELERO, I. et al., Nature Medicine, (19970000), vol. 3, pages 682 - 685
    - HUTLOFF, A. et al., Nature, (19990000), vol. 400, pages 173 - 177
    - HOLLIGER, Proc. Natl. Acad. Sci. USA, (19930000), vol. 90, pages 6444 - 6448
    - POLJAK, Structure, (19940000), vol. 2, pages 1121 - 1123
    - OVERWIJK, W. et al., Proc. Natl. Acad. Sci. U.S.A., (19990000), vol. 96, pages 2982 - 2987
    - ROSENBERG, S AWHITE, D E, J. Immunother Emphasis Tumor Immunol, (19960000), vol. 19, no. 1, pages 81 - 4
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.